Optimer Pharmaceuticals, Inc. (OPTR) Downgraded by Zacks to UNDERPERFORM

Zacks Zacks Investment Research downgraded shares of Optimer Pharmaceuticals, Inc. (OPTR) from NEUTRAL to UNDERPERFORM on May 07, 2013, with a target price of $14.00.

We are downgrading Optimer Pharma to Underperform from Neutral due to the company's bleak long-term growth prospects. Optimer is solely dependent Dificid for growth. In the absence of a decent pipeline, Optimer has little to fall back on in the event of Dificid performing below expectations. Moreover, Dificid operates in a highly competitive environment. Competition in the CDAD space is expected to intensify with the potential approval of Cubist Pharma's surotomycin, currently in phase III development. In view of these negatives, we advise long-term investors to avoid the stock at current levels. Our target price is at $14.00.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on Optimer Pharmaceuticals, Inc. (OPTR),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .

Be the first to comment

Leave a Reply